These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 16648318)

  • 21. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
    Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
    Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.
    Assunção SS; Ruschel SI; Rosa Lde C; Campos JA; Alves MJ; Bracco OL; de Lima MS
    Braz J Psychiatry; 2006 Dec; 28(4):270-6. PubMed ID: 17242805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
    Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine treatment of residual positive and negative symptoms.
    Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
    Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
    Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
    J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
    Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
    Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
    Lecrubier Y; Quintin P; Bouhassira M; Perrin E; Lancrenon S
    Acta Psychiatr Scand; 2006 Nov; 114(5):319-27. PubMed ID: 17022791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study.
    Zanarini MC; Schulz SC; Detke HC; Tanaka Y; Zhao F; Lin D; Deberdt W; Kryzhanovskaya L; Corya S
    J Clin Psychiatry; 2011 Oct; 72(10):1353-62. PubMed ID: 21535995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
    Hamilton SH; Revicki DA; Genduso LA; Beasley CM
    Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
    Silva de Lima M; de Jesus Mari J; Breier A; Maria Costa A; Pondé de Sena E; Hotopf M
    J Clin Psychiatry; 2005 Jul; 66(7):831-8. PubMed ID: 16013897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
    De Deyn PP; Carrasco MM; Deberdt W; Jeandel C; Hay DP; Feldman PD; Young CA; Lehman DL; Breier A
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):115-26. PubMed ID: 14758577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
    Tohen M; Sanger TM; McElroy SL; Tollefson GD; Chengappa KN; Daniel DG; Petty F; Centorrino F; Wang R; Grundy SL; Greaney MG; Jacobs TG; David SR; Toma V
    Am J Psychiatry; 1999 May; 156(5):702-9. PubMed ID: 10327902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.